Looking back: does adding a new drug help fight rare brain cancer?
NCT ID NCT06115824
Summary
This completed study looked back at the medical records of 136 patients with a rare brain cancer called primary central nervous system lymphoma (PCNSL). Researchers compared two treatment approaches: one using a standard chemotherapy drug (methotrexate) and another combining that same drug with a newer medication (orelabrutinib). The goal was to see if adding the new drug led to better outcomes, like longer survival or more effective tumor shrinkage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Hematology, Huashan Hospital, Fudan University
Shanghai, China
Conditions
Explore the condition pages connected to this study.